RATIO-SALBUTAMOL SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

SALBUTAMOL (SALBUTAMOL SULFATE)

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

R03AC02

SNN (starptautisko nepatentēto nosaukumu):

SALBUTAMOL

Deva:

2MG

Zāļu forma:

SOLUTION

Kompozīcija:

SALBUTAMOL (SALBUTAMOL SULFATE) 2MG

Ievadīšanas:

INHALATION

Vienības iepakojumā:

2.5ML

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108887001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2018-06-22

Produkta apraksts

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate nebules P.F. 1.25MG/2.5 ML, 5.0 MG/2.5 ML AMPOULES
Bronchodilator
(beta
2
-adrenergic stimulant)
TEVA CANADA LIMITED..
30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA, M1B 2K9
Control: 165512
DATE OF PREPARATION:
JULY 3, 2013
Teva Canada Limited.
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
7
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................